Nordic Nanovector to Present Preclinical Data Demonstrating Betalutin® Reverses Resistance to Anti-CD20 Treatment in NHL Cells

Nordic Nanovector to Present Preclinical Data Demonstrating Betalutin® Reverses Resistance to Anti-CD20 Treatment in NHL Cells

June 11, 2018 Poster to be presented at Inaugural AACR International Meeting: Advances in Malignant Lymphoma OSLO, Norway, June 11, 2018 /PRNewswire/ — Nordic Nanovector ASA (OSE: NANO) announces that a poster reporting the ability of Betalutin® (177Lu-lilotomab satetraxetan) to reverse resistance

Nordic Nanovector Announces PARADIGME Trial Approved to Start in Norway

Nordic Nanovector Announces PARADIGME Trial Approved to Start in Norway

OSLO, Norway, May 29, 2018 /PRNewswire/ — Nordic Nanovector ASA (OSE: NANO) announces that its pivotal PARADIGME Phase 2b trial with Betalutin® (177Lu-satetraxetan-lilotomab) in third-line (3L) follicular lymphoma (FL) patients has been approved by the Regional Committees for Medical and Health Research Ethics